Información del artículo
El Texto completo está disponible en PDF
References
[1.]
M.H.A. Court.
pharmacogenomics primer.
J Clin Pharmacol, 47 (2007), pp. 1087-1113
[2.]
S. Mas, A. Lafuente.
Pharmacogenetics strategies: from candidate genes to whole-genome association analysis. Exploratory or confirmatory studies?.
Curr Pharmacogenetics Personalized Med, 7 (2009), pp. 59-69
[3.]
E. Segal, N. Friedman, N. Kaminski, A. Reger, D. Koller.
From signatures to models: understanding cancer with microarrays.
Nat Genet, 37 (2005), pp. 38-45
[4.]
I.H.A. Consortium.
A haplotype map of the Human Genome.
Nature, 437 (2005), pp. 1299-1320
[5.]
K.L. Gunderson, K.M. Kuhn, F.J. Steeners, P. Ng, S.S. Murray, R. Shen.
Whole genome genotyping of haplotype tagg single nucleotide polymorphisms.
Pharmacogenomics J, 7 (2006), pp. 641-648
[6.]
D.J. Balding.
A tutorial on statistical methods for population association studies.
Nat Rev, 7 (2006), pp. 781-791
[7.]
T. Inada, M. Koga, H. Ishiguro, Y. Horiuchi, A. Syu, T. Yoshio, et al.
Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gammaaminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
Pharmacogenet Genomics, 18 (2008), pp. 317-323
[8.]
C. Lavedan, L. Licamele, S. Volpi, J. Hamilton, C. Heaton, K. Mack, et al.
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.
Mol Psychiatry, 14 (2009), pp. 804-819
[9.]
S. Volpi, C. Heaton, K. Mack, J.B. Hamilton, R. Lannan, C.D. Wolfgang, et al.
Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.
Mol Psychiatry, 14 (2009), pp. 1024-1031
[10.]
J.L. McClay, D.E. Adkins, K. Aberg, J. Bukszár, A.N. Khachane, R.S. Keefe, et al.
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.
Neuropsychopharmacology, 36 (2011), pp. 616-626
[11.]
L. Greenbaum, A. Alkelai, A. Rigbi, Y. Kohn, B. Lerer.
Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia.
Mov Disord, 25 (2010), pp. 2809-2817
[12.]
K. Aberg, D.E. Adkins, Y. Liu, J.L. McClay, J. Bukszár, P. Jia, et al.
Genome-wide association study of antipsychotic-induced QTc interval prolongation.
Pharmacogenomics J, (2010),
[13.]
D.E. Adkins, K. Aberg, J.L. McClay, J. Bukszár, Z. Zhao, P. Jia, et al.
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.
Mol Psychiatry, 16 (2011), pp. 321-332
[14.]
A. Alkelai, L. Greenbaum, A. Rigbi, K. Kanyas, B. Lerer.
Genomewide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.
Psychopharmacology (Berl), 206 (2009), pp. 491-499
[15.]
K. Aberg, D.E. Adkins, J. Bukszár, B.T. Webb, S.N. Caroff, D. Miller del, et al.
Genomewide association study of movement-related adverse antipsychotic effects.
Biol Psychiatry, 67 (2010), pp. 279-282
[16.]
J.L. McClay, D.E. Adkins, K. Aberg, S. Stroup, D.O. Perkins, V.I. Vladimirov, et al.
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.
Mol Psychiatry, 16 (2011), pp. 76-85
[17.]
M. Ikeda, Y. Tomita, A. Mouri, M. Koga, T. Okochi, R. Yoshimura, et al.
Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.
Biol Psychiatry, 67 (2010), pp. 263-269
[18.]
A. Syu, H. Ishiguro, T. Inada, Y. Horiuchi, S. Tanaka, M. Ishikawa, et al.
Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.
Neuropsychopharmacology, 35 (2010), pp. 1155-1164
[19.]
A. Valiente, A. Lafuente, M. Bernardo.
Avances en la genética de la esquizofrenia. Revisión sistemática de estudios GWAS.
Rev Psiquiatr Salud Ment, (2011),
[20.]
A. Lafuente, M. Bernardo, S. Mas, A. Crescenti, M. Aparici, P. Gassó, et al.
Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
Schizophr Res, 90 (2007), pp. 115-122
[21.]
A. Crescenti, S. Mas, P. Gassó, E. Parellada, M. Bernardo, Lafuente A.
Cyp2d6*3, *4 *5 and *6 polymorphisms and antipsychoticinduced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Clin Exp Pharmacol Physiol, 35 (2008), pp. 807-811
[22.]
A. Lafuente, M. Bernardo, S. Mas, A. Crescenti, M. Aparici, P. Gasso, et al.
Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.
Psychiatry Res, 161 (2008), pp. 131-141
[23.]
P. Gassó, S. Mas, M. Bernardo, S. Alvarez, E. Parellada, A. Lafuente.
common variant in DRD3 gene is associated with risperidoneinduced extrapyramidal symptoms.
Pharmacogenomics J, 9 (2009), pp. 404-410
[24.]
P. Gassó, S. Mas, A. Crescenti, S. Alvarez, G. Parramon, C. Garcia-Rizo, et al.
Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes.
Psychiatry Res, 175 (2010), pp. 173-175
[25.]
P. Gassó, S. Mas, C. Oliveira, M. Bioque, E. Parellada, M. Bernardo, et al.
Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients.
Eur Neuropsychopharmacol, 21 (2010), pp. 294-299
[26.]
S. Mas, P. Gassò, S. Alvarez, E. Parellada, M. Bernardo, A. Lafuente.
Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes.
Pharmacogenomics J, (2010),
Copyright © 2011. SEP y SEPB